Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>Events>This Event
  Events - November 2013

Clinical Trials in CNS

18 Nov 2013 - 19 Nov 2013 - London, UK

Bookmark and Share

SMi is proud to present the 12th Annual...

Clinical Trials in CNS

The highly anticipated and respected 12th annual Clinical Trials in CNS Conference returns to London with a two day content packed agenda featuring new approaches taken in this field towards a number of neurodegenerative disorders, from clinical trial modelling and simulation to the role of biomarkers, the agenda presents a detailed look into many aspects of drug discovery and delivery of CNS therapeutics. This innovative conference will give delegates an opportunity to gain insights through case studies and interactive discussion into the best practices in clinical trials. 

>>>>>Event highlights include:

Learn the importance of understanding the pathophysiology and biology of disease processes with use of biomarkers and imaging techniques

Discover ways to design late stage clinical trials

Overcome challenges of delivery within the CNS

Determine the legal and ethical issues behind sham surgery


Larry Alphs, Therapeutic Area Leader, Johnson & Johnson

Lars Bauer, Senior Medical Director TA CNS, UCB Pharma

Tom Isaacs, Co-founder, Cure Parkinson’s Trust

Kyriacos Mitrophanous, Head of Research, Oxford Biomedica

Mathieu Albasser, Post Doctoral Researcher, Eli Lilly 

Johannes Streffer, Senior Director, Experimental Medicine Europe, Janssen Research & Development

Warren Hirst, Associate Research Fellow Neurodegeneration Research, Pfizer

Eric Karran, Director of Research, Alzheimers Research UK



Defining Clinical Relevance

Workshop Leaders: Susan Mcgoldrick, Managing Director, QCTR

Audrey Jamieson, Business Development Manager, QCTR

08.30 - 12.30

**Book by 19th July 2013 and save £300**

**Book by 31st September 2013 and save £100**

Visit our website here:

Alternatively, contact: Jonathan Collins on +44 (0)20 7827 6734 or email:

Academic & Group discounts available

Further information
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos